ArticleCureus2026
Mesonephric-Like Adenocarcinoma of the Endometrium: A Rare and Diagnostically Challenging Entity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesonephric-like adenocarcinoma (MLA) is a recently recognized and rare entity. It is a morphologically distinctive carcinoma of the uterine corpus, estimated to account for approximately 1% of endometrial malignancies. Its diagnosis is particularly challenging owing to morphological and immunophenotypic overlap with cervical mesonephric adenocarcinoma and other endometrial carcinoma subtypes. Accurate identification has significant clinical implications given its association with aggressive behavior. We report the case of a 62-year-old postmenopausal woman who presented with a two-day history of postmenopausal vaginal bleeding. A PET/MR fusion scan revealed a metabolically active, T2-hyperintense lesion involving the posterior uterine wall and lower uterine segment, associated with haematometra. She underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy and comprehensive surgical staging. Histopathological examination demonstrated a high-grade carcinoma with tumor cells arranged in small tubules, nests, and sheets, containing intraluminal eosinophilic secretions, a pattern characteristic of mesonephric-like differentiation. Immunohistochemistry showed diffuse positivity for GATA3 and PAX8, with wild-type p53 expression, supporting the diagnosis of MLA. Tumor invasion exceeded 50% of the myometrial thickness (93.75%), with negative lymph nodes and clear surgical margins, yielding a final stage of pT1b pN0 (the International Federation of Gynecology and Obstetrics (FIGO) stage IIC). This report underscores the critical importance of integrating classical morphological assessment with a targeted immunohistochemical panel in diagnosing MLA. As this entity is increasingly recognized, pathologists must maintain a high index of suspicion, particularly in postmenopausal women with tumors exhibiting tubular architecture and eosinophilic luminal secretions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.